Danish biotech leader Genmab has officially launched an 'AI Everywhere' initiative by fully embracing ChatGPT Enterprise. This strategic adoption is specifically supported by OpenAI's robust commitments to enterprise-grade security and data privacy, which are critical requirements for handling sensitive pharmaceutical research and patient data. By integrating these advanced AI tools, Genmab aims to significantly accelerate its drug discovery pipelines and streamline complex R&D workflows.

This move signals a major shift within the biopharma industry, where companies are increasingly leveraging generative AI to maintain a competitive edge. The partnership highlights how specialized life sciences firms are moving beyond experimentation to full-scale implementation of AI technologies to drive innovation and operational efficiency. Ultimately, this collaboration serves as a bellwether for the future of AI-driven biotechnology and drug development.